Author

Kenneth Dawes

Observed name: Kenneth W. Dawes

Observed institution: Dawes Fretzin Clinical Research Group

OpenAlex ID: A5110168782

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

2022 · Ellen J. Kim, Aaron R. Mangold, et al. · JAMA Dermatology · 56

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea

2025 · Neal Bhatia, James Del Rosso, et al. · JAMA Dermatology · 13

52244 Early Improvement in Nail and Scalp Psoriasis from a Prospective Observational Study of Patients with Psoriasis in Special Areas (PSoSA) Initiating Ixekizumab: Results from the First Interim Analysis

2024 · Jerry Bagel, Kenneth Dawes, et al. · Journal of the American Academy of Dermatology · 2

62422 Ixekizumab Improves Musculoskeletal Symptoms Measured by the IDEOM MSK-8 Questionnaire in Patients with Psoriasis and PEST Scores <3 or ≥3: Results from the Real-World Psoriasis in Special Areas (PSoSA) Study

2025 · Alice Gottlieb, Lourdes Perez-Chada, et al. · Journal of the American Academy of Dermatology

Works count: 4

Citation count: 71

H-index: 2

I10-index: 2